As advanced therapies and vaccines reshape healthcare, Wacker ­Biotech is emerging as a CDMO partner of choice. With decades ...

French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics' muscular dystrophy business.

Swedish biotech Alligator Bioscience has agreed to sell its CD40-targeting cancer immunotherapy mitazalimab to Canadian drug ...

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research ...

Italy's Menarini Group will pay Maryland biotech Georgiamune $45 million (€40 million) in upfront and near-term payments, in ...

Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for ...

Denmark's Genmab said adding its bispecific antibody petosemtamab to MSD's Keytruda (pembrolizumab) cut the risk of death by ...

Swiss pharma group Ferring Pharmaceuticals has agreed to acquire New York-based Gameto for up to $1.3825 billion (€1.24 ...

Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s ...

Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics ...

Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions ...

Switzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits ...